ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 985

Heart Failure Hospitalizations Among SLE and Diabetes Mellitus Patients Compared to the General U.S. Medicaid Population

Sarah Chen1, Medha Barbhaiya2, Michael A. Fischer3, Hongshu Guan4, Candace H. Feldman5, Brendan M. Everett6 and Karen H. Costenbader7, 1Brigham and Women's Hospital, Boston, MA, 2Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 3Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 4Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 5Rheumatology, Brigham & Women's Hospital, Boston, MA, 6Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 7Brigham and Women's Hospital, Harvard Medical School, Boston, MA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: SLE and cardiovascular disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Epidemiology and Public Health Poster II: Rheumatic Diseases Other than Rheumatoid Arthritis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Cardiovascular disease (CVD) risk is increased in SLE patients, compared to the general population and age- and sex-matched diabetes mellitus (DM) patients. Heart failure (HF) is the leading cause of hospitalizations in the U.S., and HF risk is elevated among DM patients compared to those without DM. Given the elevated CVD risk in SLE patients, we investigated rates and risks of HF hospitalization among SLE patients and age- and sex-matched DM and general Medicaid patients.

Methods: We used Medicaid Analytic eXtract (MAX) data, containing billing claims for Medicaid patients from the 29 most populated US states, 2007-2010. We identified both SLE and DM patients, ages 18-65, using >3 ICD-9 codes for SLE or DM, each separated by >30 days. Index date was the date of the 3rd diagnosis code. We matched each SLE patient at index date to 2 DM patients and 4 general Medicaid patients without SLE or DM, by age at index date and sex. (The general Medicaid cohort had non-SLE, non-DM ICD-9 codes on date of SLE index date.) We required a baseline period of 6 months of continuous Medicaid enrollment prior to the index date for all patients. Subjects were followed from index date until death, disenrollment or end of follow-up. We used ICD-9 codes to identify HF as primary or secondary hospital discharge diagnosis and calculated rates of first HF hospitalization event per 1,000 person-years for each cohort. We used Cox proportional hazard models to calculate hazard ratios (HR) for first HF hospitalization events. In a secondary analysis, we excluded those with baseline HF.

Results: 40,212 SLE patients were matched to 80,424 DM and 160,848 general patients. In all cohorts, 92% were female, and mean age was 40.3 (+12.1) years. Mean follow up was 1.8 (+1.1) years for SLE, 1.8 (+1.1) years for DM, and 1.6 (+1.2) years for general patients. Baseline CVD was prevalent in 18% of SLE, 13% of DM and 1% of non-SLE, non-DM cohorts, and baseline HF was prevalent in 6% of SLE, 5% of DM and <1% of non-SLE, non-DM patients. HF hospitalization rates per 1,000-person years were similar in SLE and DM, but lower in the general population (Table). Adjusted HRs for first HF hospitalizations were higher among DM (HR 4.0, 95% CI 3.6-4.3) and SLE (HR 2.4, 95% CI 2.2-2.7) patients compared to non-SLE, non-DM patients. When patients with baseline HF were excluded, the HR for first HF hospitalizations were similar between SLE (HR 2.5, 95% CI 2.3-2.8) and DM (HR 2.7, 95% CI 2.4-2.9).

Conclusion: SLE and age- and sex-matched DM patients had significantly higher rates of HF hospitalization than age- and sex-matched general (non-SLE, non-DM) Medicaid patients. The adjusted risk of first HF hospitalization was also over twice as high in both SLE and DM patients than in patients without either condition, which has important implications for improving clinical care for SLE patients.

Table. Rates and Multivariable Hazard Ratios for Hospitalizations for HF* among SLE Patients and Age- and Sex-Matched DM Patients, compared to the General (non-SLE, non-DM) Medicaid population, 2007-2010

Cohort†

Events

Person-years

Rate‡ (95% CI)

HR§ (95% CI)

Including all patients

Excluding patients with baseline HF

General Medicaid

620

250,281

2.5 (2.3-2.7)

1.0 (ref)

1.0 (ref)

SLE

837

73,299

11.4 (10.7-12.2)

2.4 (2.2-2.7)

2.5 (2.3-2.8)

Diabetes Mellitus

1,675

145,692

11.5 (11.0-12.1)

4.0 (3.6-4.3)

2.7 (2.4-2.9)

*HF: Heart failure events by hospitalization ICD-9 diagnosis codes 402.01, 402.11, 402.91, 404.01, 404.11, 404.91, 404.03, 404.13, 404.93, and 428.xx, but excluding 398.91 rheumatic heart disease (Chen J, Circulation, 2013).

†Cohort: SLE cohort defined as >3 SLE ICD-9 codes (710.0), each separated by >30 days; DM cohort defined as >3 ICD-9 codes (249.XX, 250.XX, 357.2, 362.01-362.06, 366.41), 1:2 matched by age, sex to SLE cohort; General Medicaid cohort defined as any non-SLE, non-DM ICD-9 code on same date as SLE index date, 1:4 matched by age, and sex to SLE cohort

‡Rate: Rate of first HF hospitalization events per 1000 person-years of follow up

§HR: Hazard ratio for first HF hospitalization event adjusted for age, sex, race/ethnicity, US region of residence, zip-code level socioeconomic status, Charlson comorbidity index; Two separate Cox proportional hazard models: 1) including all patients, 2) excluding patients who had baseline HF diagnosis


Disclosure: S. Chen, None; M. Barbhaiya, None; M. A. Fischer, None; H. Guan, None; C. H. Feldman, None; B. M. Everett, None; K. H. Costenbader, None.

To cite this abstract in AMA style:

Chen S, Barbhaiya M, Fischer MA, Guan H, Feldman CH, Everett BM, Costenbader KH. Heart Failure Hospitalizations Among SLE and Diabetes Mellitus Patients Compared to the General U.S. Medicaid Population [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/heart-failure-hospitalizations-among-sle-and-diabetes-mellitus-patients-compared-to-the-general-u-s-medicaid-population/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/heart-failure-hospitalizations-among-sle-and-diabetes-mellitus-patients-compared-to-the-general-u-s-medicaid-population/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology